BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol 2018;113:1197-205. [PMID: 29925913 DOI: 10.1038/s41395-018-0144-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Johnson CM, Linzay CD, Dassopoulos T. Maneuvering Clinical Pathways for Ulcerative Colitis. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0716-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Singh S, Kim J, Zhu W, Dulai PS, Sandborn WJ, Jairath V. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther 2020;52:481-91. [PMID: 32573825 DOI: 10.1111/apt.15876] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
3 Ballester MP, Marti-aguado D, Fullana M, Bosca-watts MM, Tosca J, Romero E, Sanchez A, Navarro-cortes P, Anton R, Mora F, Minguez M. Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system. Int J Colorectal Dis 2019;34:1053-9. [DOI: 10.1007/s00384-019-03271-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
4 Ma C, Guizzetti L, Cipriano LE, Parker CE, Nguyen TM, Gregor JC, Chande N, Feagan BG, Jairath V. Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. Aliment Pharmacol Ther 2019;49:364-74. [PMID: 30569460 DOI: 10.1111/apt.15090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Ungaro RC, Limketkai BN, Jensen CB, Allin KH, Agrawal M, Ullman T, Colombel JF, Jess T. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Gut 2019;68:977-84. [PMID: 30420398 DOI: 10.1136/gutjnl-2018-317021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
6 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 300] [Cited by in F6Publishing: 254] [Article Influence: 100.0] [Reference Citation Analysis]
7 AlAskar D, AlSardi M, Al Sulais E, Mosli M, AlAmeel T. Risk of neutropenia in inflammatory bowel disease patients treated with TNF inhibitors: A single-center, retrospective cohort study. Saudi J Gastroenterol 2020. [PMID: 32496224 DOI: 10.4103/sjg.SJG_41_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med 2019;9:E94. [PMID: 31905945 DOI: 10.3390/jcm9010094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
9 Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
10 Naganuma M. Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis. J Gastroenterol 2020;55:1013-22. [PMID: 32778960 DOI: 10.1007/s00535-020-01713-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chapman TP, Frias Gomes C, Louis E, Colombel J, Satsangi J. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:73-84. [DOI: 10.1111/apt.15771] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
12 Ungaro RC, Brenner EJ, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021;70:725-32. [PMID: 33082265 DOI: 10.1136/gutjnl-2020-322539] [Cited by in Crossref: 148] [Cited by in F6Publishing: 125] [Article Influence: 148.0] [Reference Citation Analysis]
13 Shaffer SR, Huang E, Patel S, Rubin DT. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol 2021;116:125-33. [PMID: 32947317 DOI: 10.14309/ajg.0000000000000847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Shaffer SR, Rubin DT. Response to Tetangco and Hanauer. Am J Gastroenterol 2021;116:1959-60. [PMID: 34101668 DOI: 10.14309/ajg.0000000000001330] [Reference Citation Analysis]
15 Frias Gomes C, Chapman TP, Satsangi J. De-escalation of medical therapy in inflammatory bowel disease. Curr Opin Pharmacol 2020;55:73-81. [PMID: 33160250 DOI: 10.1016/j.coph.2020.09.014] [Reference Citation Analysis]
16 Singh S, Jairath V. Response to Gupta and Hanauer. Am J Gastroenterol 2019;114:535-6. [PMID: 30789422 DOI: 10.14309/ajg.0000000000000160] [Reference Citation Analysis]
17 Balram B, Joshi H, Wong K, Kroeker KI, Dieleman LA, Halloran BP, Baumgart DC, Peerani F. Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial. Dig Dis Sci 2021;66:3985-92. [PMID: 33184796 DOI: 10.1007/s10620-020-06704-6] [Reference Citation Analysis]
18 Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opinion on Biological Therapy 2020;20:363-78. [DOI: 10.1080/14712598.2019.1666101] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
19 Ma C, Kotze PG, Almutairdi A, Jairath V, Panaccione R. Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab. Clin Gastroenterol Hepatol 2019;17:2374-2376.e2. [PMID: 30528845 DOI: 10.1016/j.cgh.2018.11.062] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
20 Baehler C, Brüngger B, Blozik E, Vavricka SR, Schoepfer AM. Real-World Data on Topical Therapies and Annual Health Resource Utilization in Hospitalized Swiss Patients with Ulcerative Colitis. Inflamm Intest Dis 2019;4:144-53. [PMID: 31768387 DOI: 10.1159/000502205] [Reference Citation Analysis]
21 Ross JS, Waldstreicher J, Bamford S, Berlin JA, Childers K, Desai NR, Gamble G, Gross CP, Kuntz R, Lehman R, Lins P, Morris SA, Ritchie JD, Krumholz HM. Overview and experience of the YODA Project with clinical trial data sharing after 5 years. Sci Data 2018;5:180268. [PMID: 30480665 DOI: 10.1038/sdata.2018.268] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
22 Ungaro RC, Limketkai BN, Jensen CB, Yzet C, Allin KH, Agrawal M, Ullman T, Burisch J, Jess T, Colombel JF. Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes. Clin Gastroenterol Hepatol 2020;18:1152-1160.e1. [PMID: 31419574 DOI: 10.1016/j.cgh.2019.08.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]